HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 342 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.30 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,920,655 | -3.1% | 207,347 | -8.5% | 0.01% | 0.0% |
| Q2 2023 | $8,174,147 | +20.1% | 226,619 | +27.2% | 0.01% | +14.3% |
| Q1 2023 | $6,804,809 | -31.3% | 178,183 | +2.3% | 0.01% | -36.4% |
| Q4 2022 | $9,908,852 | +47.0% | 174,145 | +2.2% | 0.01% | +37.5% |
| Q3 2022 | $6,740,000 | -7.6% | 170,461 | +2.8% | 0.01% | 0.0% |
| Q2 2022 | $7,294,000 | +8.3% | 165,779 | -1.8% | 0.01% | +33.3% |
| Q1 2022 | $6,734,000 | -0.3% | 168,852 | +0.5% | 0.01% | +50.0% |
| Q4 2021 | $6,757,000 | -5.2% | 168,039 | -4.1% | 0.00% | 0.0% |
| Q3 2021 | $7,125,000 | +4.2% | 175,138 | +16.3% | 0.00% | 0.0% |
| Q2 2021 | $6,841,000 | +5.5% | 150,656 | -3.1% | 0.00% | +33.3% |
| Q1 2021 | $6,484,000 | -41.6% | 155,532 | -40.2% | 0.00% | -40.0% |
| Q4 2020 | $11,102,000 | +157.8% | 259,918 | +58.6% | 0.01% | +66.7% |
| Q3 2020 | $4,306,000 | -29.3% | 163,852 | -27.8% | 0.00% | -25.0% |
| Q2 2020 | $6,087,000 | +246.6% | 227,030 | +132.5% | 0.00% | +100.0% |
| Q1 2020 | $1,756,000 | -44.3% | 97,651 | -45.1% | 0.00% | 0.0% |
| Q4 2019 | $3,155,000 | +37.2% | 177,987 | +20.1% | 0.00% | 0.0% |
| Q3 2019 | $2,299,000 | -40.9% | 148,163 | -34.6% | 0.00% | -33.3% |
| Q2 2019 | $3,890,000 | +19.1% | 226,498 | +11.6% | 0.00% | 0.0% |
| Q1 2019 | $3,266,000 | +42.6% | 202,873 | +29.5% | 0.00% | +50.0% |
| Q4 2018 | $2,291,000 | +30.9% | 156,665 | +62.7% | 0.00% | 0.0% |
| Q3 2018 | $1,750,000 | -6.4% | 96,290 | -13.1% | 0.00% | 0.0% |
| Q2 2018 | $1,869,000 | -36.9% | 110,829 | -26.7% | 0.00% | -33.3% |
| Q1 2018 | $2,961,000 | +18.1% | 151,125 | +22.1% | 0.00% | +50.0% |
| Q4 2017 | $2,507,000 | -47.6% | 123,772 | -55.1% | 0.00% | -60.0% |
| Q3 2017 | $4,784,000 | +51.4% | 275,458 | +11.7% | 0.01% | +66.7% |
| Q2 2017 | $3,159,000 | -6.7% | 246,513 | -5.7% | 0.00% | 0.0% |
| Q1 2017 | $3,386,000 | +158.7% | 261,374 | +97.2% | 0.00% | +200.0% |
| Q4 2016 | $1,309,000 | -78.9% | 132,513 | -74.2% | 0.00% | -83.3% |
| Q3 2016 | $6,197,000 | +42.0% | 512,921 | +1.4% | 0.01% | +20.0% |
| Q2 2016 | $4,364,000 | -12.9% | 505,652 | -4.4% | 0.01% | -16.7% |
| Q1 2016 | $5,009,000 | -63.5% | 529,047 | -33.1% | 0.01% | -62.5% |
| Q4 2015 | $13,708,000 | +18.6% | 790,986 | -8.1% | 0.02% | +14.3% |
| Q3 2015 | $11,563,000 | -47.2% | 860,934 | -11.2% | 0.01% | -33.3% |
| Q2 2015 | $21,903,000 | +76.2% | 970,048 | +11.4% | 0.02% | +75.0% |
| Q1 2015 | $12,430,000 | -2.1% | 870,430 | -33.8% | 0.01% | +9.1% |
| Q4 2014 | $12,695,000 | +12.2% | 1,315,473 | +5.8% | 0.01% | +22.2% |
| Q3 2014 | $11,319,000 | +34.0% | 1,243,901 | +45.5% | 0.01% | +28.6% |
| Q2 2014 | $8,445,000 | -18.1% | 854,812 | +5.4% | 0.01% | -30.0% |
| Q1 2014 | $10,307,000 | +98.9% | 811,193 | +134.6% | 0.01% | +100.0% |
| Q4 2013 | $5,183,000 | +36.8% | 345,816 | +0.8% | 0.01% | +25.0% |
| Q3 2013 | $3,789,000 | +181.1% | 343,146 | +102.3% | 0.00% | +300.0% |
| Q2 2013 | $1,348,000 | -15.4% | 169,632 | -38.7% | 0.00% | -50.0% |
| Q1 2013 | $1,594,000 | – | 276,528 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,829,337 | $266,308,000 | 10.60% |
| BB BIOTECH AG | 6,929,832 | $93,068,000 | 2.95% |
| SECTORAL ASSET MANAGEMENT INC | 2,671,051 | $35,872,000 | 1.64% |
| Sterling Global Strategies LLC | 22,000 | $295,000 | 1.63% |
| Lombard Odier Asset Management (USA) Corp | 1,061,547 | $14,257,000 | 1.24% |
| PYRRHO CAPITAL MANAGEMENT, LP | 90,000 | $1,209,000 | 1.04% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 8,184,003 | $109,911,000 | 0.93% |
| Bellevue Asset Management AG | 246,000 | $3,304,000 | 0.54% |
| Convergence Investment Partners, LLC | 251,748 | $3,381,000 | 0.39% |
| Rhenman & Partners Asset Management AB | 172,000 | $2,310,000 | 0.37% |